Mounjaro in North Carolina (2026)
tirzepatide · GLP-1 weight management · North Carolina
About Mounjaro
FDA-approved tirzepatide for type 2 diabetes. Off-label for weight loss is common.
See the full Mounjaro review for dosing, efficacy data, side effects, and the full pharmacy + telehealth program comparison.
Insurance coverage for Mounjaro in North Carolina
NC Medicaid covers GLP-1s for weight management with prior authorization (criteria effective August 1, 2024). Coverage was paused on October 1, 2025 and reinstated on December 12, 2025. Wegovy is the preferred drug; Zepbound and Saxenda require a trial of Wegovy first.
| Carrier | Mounjaro status | Detail |
|---|---|---|
| Aetna | Covered | Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Aetna coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Blue Cross Blue Shield | Covered (prior auth required) | Blue Cross Blue Shield of Massachusetts continues to cover Mounjaro for type 2 diabetes with prior authorization that includes a documented diabetes diagnosis, after ending weight-loss GLP-1 coverage in 2026. Other Blue plans set their own rules. |
| UnitedHealthcare | Covered | Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public UnitedHealthcare coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Cigna | Covered | Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Cigna coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Humana | Covered | Medicare Part D, including Humana drug plans, covers Mounjaro for type 2 diabetes. Check Humana's formulary for your plan's tier and prior authorization rules. |
| Kaiser Permanente | Covered | Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Kaiser Permanente coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Anthem | Covered | Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Anthem commercial coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Medicare | Covered | Part D plans cover Mounjaro for type 2 diabetes; tier and prior authorization depend on your plan's formulary. People with type 2 diabetes get GLP-1s through their Part D plan and cannot use the Medicare GLP-1 Bridge. |
| Medicaid | Covered | MassHealth lists Mounjaro as a preferred GIP/GLP-1 drug for diabetes, and California Medi-Cal keeps Mounjaro on its drug list restricted to type 2 diabetes. Neither covers it for weight loss. |
| TRICARE | Covered (prior auth required) | TRICARE covers Mounjaro for type 2 diabetes for all beneficiaries with prior authorization, plus a medical necessity form for the formulary copayment and for coverage at a military pharmacy. |
Telehealth and prescribing in North Carolina
A telehealth clinician must be licensed in North Carolina to prescribe Mounjaro to you while you are in North Carolina.
North Carolina joined the Interstate Medical Licensure Compact effective January 1, 2026 (Session Law 2025-37).
- Source: NC Medical Board: IMLC
Platforms differ in which drugs they prescribe, insurance handling, and clinical model. See our platform comparisons.
Compounded tirzepatide
On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.
Mounjaro in North Carolina: common questions
Is Mounjaro legal in North Carolina?+
Yes. Mounjaro (tirzepatide) is FDA-approved and legal in all 50 US states including North Carolina. State-level differences appear in Medicaid coverage and clinician licensing, not in the legality of the medication itself.
Can I get Mounjaro via telehealth in North Carolina?+
Yes, from a clinician licensed in North Carolina. A telehealth clinician must be licensed in North Carolina to prescribe Mounjaro to you while you are in North Carolina. North Carolina joined the Interstate Medical Licensure Compact effective January 1, 2026 (Session Law 2025-37).
Does North Carolina Medicaid cover Mounjaro?+
Covered with prior authorization for weight loss. NC Medicaid covers GLP-1s for weight management with prior authorization (criteria effective August 1, 2024). Coverage was paused on October 1, 2025 and reinstated on December 12, 2025. Wegovy is the preferred drug; Zepbound and Saxenda require a trial of Wegovy first.
What's the cheapest way to get Mounjaro in North Carolina?+
The main paths are insurance with prior authorization if your plan covers it, manufacturer cash-pay programs, or telehealth programs that include the medication. NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.
Is compounded Mounjaro still available in North Carolina?+
Compounding rules are federal, not set by North Carolina. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.